July 10, 2018
July 10, 2019
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Paradigm Medical Communications, LLC.
This activity is supported by an educational grant from Merck & Co., Inc.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Pharmacists — 1.0 contact hours (0.10 CEUs)
All other health care professionals completing this course will be issued a statement of participation.
This activity has been designed to meet the educational needs of community medical oncologists and advanced practitioners, such as nurse practitioners, PAs, and pharmacists, treating genitourinary (GU) cancers, including renal cell carcinoma and bladder cancer. This activity may also benefit other oncology healthcare professionals involved in the management of patients with renal cell carcinoma and bladder cancer.
This case-based enduring activity will cover the principles of immunology as they relate to the mechanisms of action of immune checkpoint inhibitors as well as the clinical profiles of these agents (as monotherapy or combination therapy) and their roles and patterns of response in first- and subsequent-line treatment of GU cancers, including bladder cancer and renal cell carcinoma, so that clinicians are better able to appropriately integrate immune checkpoint inhibitors into clinical practice for treatment of patients with GU cancers.
Statement of Need
To provide high-quality, evidence-based care, oncologists must be familiar with the principles of immunology as they relate to the mechanisms of action of immune checkpoint inhibitors as well as the clinical profiles of these agents (as monotherapy or combination therapy) and their roles and patterns of response in first- and subsequent-line treatment of GU cancers, including bladder cancer and renal cell carcinoma. This activity will educate clinicians how to appropriately integrate immune checkpoint inhibitors into clinical practice for treatment of patients with GU cancers.
Upon completion of this activity, participants should be able to:
- Describe the principles of immunology as they relate to the mechanisms of action and pathways of immune checkpoint inhibitors in the treatment of genitourinary cancers, including renal cell and bladder cancer.
- Incorporate the latest efficacy data and clinical profiles of new and emerging immune checkpoint inhibitors into optimal management decisions, including recognition of patterns of response, in patients with genitourinary cancer, including renal cell and bladder cancer.
- Evaluate approaches to manage immune-related adverse effects associated with immune checkpoint inhibitors in patients with genitourinary cancer, including renal cell and bladder cancer.
Table of Contents
- Immuno-oncology Principles in Genitourinary Cancers
- Case 1: Newly Diagnosed Metastatic Bladder Cancer
- Case 2: Newly Diagnosed Metastatic Renal Cell Carcinoma
- Managing Immune-Related Adverse Events
Mayer N. Fishman, MD, PhD
Senior Member, Medical Oncologist
Department of Genitourinary Oncology
Department of Immunology
Moffitt Cancer Center
Department of Oncologic Sciences
Department of Internal Medicine
University of South Florida Morsani College of Medicine
Sumanta Kumar Pal, MD
Associate Clinical Professor
Department of Medical Oncology & Therapeutics Research
Co-director, Kidney Cancer Program
City of Hope
Physician Accreditation Statement
Paradigm Medical Communications, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physician Credit Designation Statement
Paradigm Medical Communications, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Accreditation and Designation Statement
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.0 hours (0.10 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. (Universal Activity Number 0761-9999-18-233-H01-P)
This is a knowledge-based activity.
This activity is jointly provided by Educational Review Systems, Inc., and Paradigm Medical Communications, LLC.
PA Continuing Education
PAs may claim a maximum of 1.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Disclosures of Conflicts of Interest
In accordance with ACCME and ACPE requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.
Mayer N. Fishman, MD, PhD
- Grant/Research Support: Bristol-Myers Squibb Company; Eisai, Inc; Hofffman-LaRoche; Medivation, Inc.
- Retained Consultant: Exelixis, Inc
Sumanta Kumar Pal, MD
- Retained Consultant: Astellas Pharma US, Inc; AVEO Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Eisai, Inc; Exelixis, Inc; Genentech, Inc.; Ipsen Biopharmaceuticals, Inc.; Novartis; Pfizer Inc; Roche.
Paradigm Medical Communications, LLC, staff members have no financial relationships to disclose.
Educational Review Systems, Inc., staff members have no financial relationships to disclose.
Independent peer reviewer has no financial relationships to disclose.
Peggy Margaret Zuckerman, Patient reviewer
- Retained Consultant: Patient-Centered Outcomes Research Institute; Roche/Genentech, Inc.
- Ownership Interest: Celgene Corporation; Gilead Sciences, Inc.
Resolution of Conflict of Interest
Paradigm Medical Communications, LLC, and Educational Review Systems, Inc., have implemented a system to resolve conflicts of interest for each CE activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CE content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACPE Guidelines and ACCME’s Standards for Commercial Support of Continuing Medical Education.
Instructions for Participation and Credit
To receive CE credit, you should:
- Follow the "Start Activity" button to go to the Paradigm Medical Communications website, where you will complete the pretest. View the online activity in its entirety.
- View the online activity in its entirety
- Complete and submit the online posttest and evaluation.
A certificate of participation/statement of completion will be available for download/printing immediately following your successful completion of the posttest and evaluation. Your certificate/statement will be saved on the Paradigm Medical Communications website and will not be available in your freeCME CME History.
Please note: to claim CPE credit, please make sure you include your date of birth and NABP number. All credit information will be uploaded into CPE Monitor within 30 days.
For questions regarding CE credit, contact the Paradigm CME Department at (845) 398-5949.
There is no fee required for participation in this activity.
This certified CE activity is designed using HTML5 video. As you navigate the video using the supplied controls, the slides will sync to the speaker.
For Desktops (Windows/Mac): Internet Explorer 9 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher
For Tablets (iPad/Android/Surface): iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher
This activity contains educational resources in Adobe Acrobat PDF format. To view the resources, you will need Adobe Reader. If you do not have Adobe Reader installed on your computer, please visit http://get.adobe.com/reader to install a free version of Adobe Reader.
If you have any technical problems or playback issues email us at email@example.com.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.
This CE activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC, or Educational Review Systems, Inc. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As an ACCME-accredited provider, Paradigm Medical Communications, LLC, activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. Any views or opinions presented are solely those of the Faculty, and do not necessarily represent those of Paradigm Medical Communications, LLC, or Educational Review Systems, Inc. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC, or Educational Review Systems, Inc. Paradigm Medical Communications, LLC, and Educational Review Systems, Inc., accept no liability for the content referenced in this activity.
Paradigm Medical Communications, LLC, and Educational Review Systems, Inc., are committed to protecting the privacy of those who participate in the activities (herein referred to as “website") located at www.paradigmmc.com. The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
Security/Safeguarding Personal Information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and User of Your Personal Information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC, and Educational Review Systems, Inc., to continuously improve the learning experience.
Paradigm Medical Communications, LLC, and Educational Review Systems, Inc., do not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC, and Educational Review Systems, Inc., will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC, and Educational Review Systems, Inc., staff members review individual test results to the extent necessary to record and track participants’ credits.
If you have any questions or comments, please email us at firstname.lastname@example.org.
©2018 Paradigm Medical Communications, LLC, except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.